Hematology

B-NHL Cell Therapy Cleared for Trials

Oncternal will soon initiate a phase 1/2 dose-escalation study of ONCT-808.

Sid Kerkar, MD, on Developing CAR T Therapies Without Lymphodepletion Chemotherapy

The vice president of oncology and research and development at Exuma Biotech discussed the company’s platforms, including CAR-TaNK cells.

Advancing Neonatal Cell Therapy Research

Newborn Cell Therapies Group at Monash University has received a $50,000 grant from Lions Cord Blood foundation.